

## Original Article

# Exploration of risk factors for weight loss in head and neck cancer patients

Patrick Dawson<sup>1</sup>, Amy Taylor<sup>2</sup>, Chris Bragg<sup>3</sup>

<sup>1</sup>Radiotherapy Department, Bexley Wing, St James University Hospital, Leeds, UK, <sup>2</sup>Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield, UK, <sup>3</sup>Sheffield Teaching Hospitals NHS Trust, Weston Park Hospital, Sheffield, UK

(Received 19 March 2015; revised 19 June 2015; accepted 21 June 2015; first published online 22 July 2015)

## Abstract

**Introduction:** Head and neck cancer patients receiving radiotherapy can experience a number of toxicities, including weight loss and malnutrition, which can impact upon the quality of treatment. The purpose of this retrospective cohort study is to evaluate weight loss and identify predictive factors for this patient group.

**Materials and methods:** A total of 40 patients treated with radiotherapy since 2012 at the study centre were selected for analysis. Data were collected from patient records. The association between potential risk factors and weight loss was investigated.

**Results:** Mean weight loss was 5 kg (6%). In all, 24 patients lost > 5% starting body weight. Age, T-stage, N-stage, chemotherapy and starting body weight were individually associated with significant differences in weight loss. On multiple linear regression analysis age and nodal status were predictive.

**Conclusion:** Younger patients and those with nodal disease were most at risk of weight loss. Other studies have identified the same risk factors along with several other variables. The relative significance of each along with a number of other potential factors is yet to be fully understood. Further research is required to help identify patients most at risk of weight loss; and assess interventions aimed at preventing weight loss and malnutrition.

**Keywords:** H&N; head and neck irradiation; malnutrition; radiotherapy; weight change

## INTRODUCTION

Radiotherapy is an important modality in head and neck (H&N) cancer management, particularly where preservation of organ function

is of concern.<sup>1,2</sup> Technological advances, such as intensity modulated radiotherapy, have allowed for dose escalation to the target volume and improved conformity, resulting in better outcomes and reduced treatment related toxicity.<sup>2</sup> Volumetric-modulated arc therapy (VMAT) utilises the rotational potential of the linear accelerator to deliver highly conformal treatments through an arc of 360°.<sup>3,4</sup>

Correspondence to: Patrick Dawson, Radiotherapy Department, Bexley Wing, St James University Hospital, Beckett Street, Leeds LS9 7TF, UK. Tel: +0 785 123 5931. E-mail: patrick.dawson@nhs.net

Changes to patient contour can impact upon the dose across the planning target volume (PTV), dose to organs at risk (OARs), or both; potentially to the extent that the plan requires modification.<sup>5,6</sup> There is evidence that VMAT plans are more susceptible to these changes,<sup>7</sup> and are more complex to amend, than three-dimensional conformal radiotherapy (3D-CRT).<sup>8,9</sup>

Image guided radiotherapy is increasingly employed as the steep isodoses of VMAT, combined with the proximity of OARs in the H&N, makes the risk and consequences of geographical miss increasingly severe.<sup>2</sup> Alongside improved targeting, the use of cone-beam computed tomography (CBCT) as an imaging modality allows for monitoring and assessment of morphological changes to the patient.<sup>10</sup>

There are two main factors effecting patient shape and contour; first, over a standard course of radiotherapy, tumour shrinkage is a possibility.<sup>5</sup> This is most apparent for virally mediated tumours such as human papilloma virus-positive squamous cell carcinoma (SCC). These tumours often present with bulky nodal disease and respond well to treatment showing a significant reduction in size as treatment progresses.<sup>8</sup>

The second factor is weight loss, as treatment progresses, related toxicities can impact upon the dietetic health of patients, which needs to be monitored to ensure patient health is maintained.<sup>11,12</sup> Unintentional weight loss is an indicator of malnutrition<sup>13</sup> and is associated with longer recovery from treatment related toxicity and reduced quality of life.<sup>14–16</sup> Furthermore, studies have suggested that malnutrition reduces overall survival.<sup>17,18</sup>

Since November 2012, the implementation of VMAT at the audit department has seen 3D-CRT for H&N cancer become obsolete and anecdotal evidence suggests that the timing, pattern and severity of side effects have changed in conjunction with the application of the VMAT technique. Identification of patients who are likely to experience weight loss can help to guide preventative action. It was the aim of this project to investigate the weight loss experienced by H&N cancer patients receiving VMAT; and whether any predictive factors can be identified.

## MATERIALS AND METHODS

This study formed part of a larger departmental audit that is investigating the impact of radiotherapy on H&N cancer patients. All data were anonymised and permission was sought and granted to carry out the audit from the Trust and data collection was in accordance with its guidelines.

### Data collection

Data were gathered from the medical records of patients who had undergone radiotherapy treatment at the audit department. Eligibility criteria were: diagnosis of H&N cancer, treatment with curative intent using VMAT and weight monitored throughout radiotherapy. Patients were selected semi-randomly to account for gender. A sample size of 40 was used to meet time constraints while remaining representative of the patient group. Data for the first five patients were collected by two independent researchers, thereafter, every tenth patient was independently verified for consistency and to eliminate researcher bias.

### Treatment

RapidArc treatments were generated in eclipse using AAA planning algorithm and delivered using Varian Clinac linear accelerators (6 MV photons) with CBCT capabilities. Patients received 60–70 Gy in 30–35 fractions. Induction chemotherapy was up to three cycles of Docetaxel, Cisplatin and 5FU. Concurrent chemoradiotherapy was up to three cycles of Cisplatin in weeks 1, 4 and 7 of radiotherapy. One patient received eight weekly infusions of Cetuximab starting 1 week before radiotherapy.

Departmental protocol states that patients should be weighed on the first day of treatment, once weekly thereafter and referred to dietetic services for weekly review. Patients who lose  $\geq 10\%$  of their body weight are admitted as an inpatient for closer monitoring and management of their condition.

An unintended reduction in body weight  $>5\%$  in 3 months is considered by some as suggestive of malnutrition,<sup>19</sup> NICE<sup>13</sup> have suggested  $>5\%$

in 3–6 months, while others studies have used >5% in 1 month, or >10% in 6 months.<sup>15</sup> Langius et al.<sup>20</sup> considers unintentional weight loss >5% during a course of radiotherapy as risking malnutrition, as have others<sup>21,22</sup>; therefore, the same value has been applied within this work.

## Analysis

Data were analysed using SPSS version 21. Descriptive statistics were used to identify variables with differences/trends in weight loss. Correlation was tested using Pearson's correlation coefficient. Owing to the small sample size when distributed among nominal variables, non-parametric tests were used to test for significance. Multiple linear regression was then used to identify predictive factors for weight loss from factors individually identified as significant ( $p = 0.05$ ). Initially all

variables were inserted, those identified as significant were then entered into the second analysis first with the remaining variables (not significant upon first analysis) entered one at a time to test for improved predictive power.

## RESULTS

Descriptive statistics of the cohort are presented in Table 1. Data were obtained for 22 male and 18 female patients. Mean age was 56.5 years ( $M = 58.4$ ;  $F = 54.3$ ). A total of 29 (72.5%) patients were diagnosed with SCC, the commonest site was oropharynx (9/22.5%), followed by oral cavity (7/17.5%). A total of 13 (32.5%) patients were node negative; 26 (65%) patients underwent surgery, 22 (55%) received chemotherapy and 25 (62.5%) received

**Table 1.** Cohort descriptives

|   | <i>n</i> (%) | Mean weight loss (kg) | Mean weight loss (%) | Weight loss >5% ( <i>n</i> (%)) |
|---|--------------|-----------------------|----------------------|---------------------------------|
| Age (years) (Mean: 57; SD: 12.2; Range 17–73) |              |                       |                      |                                 |
| ≤39   | 2 (5)        | 10.1                  | 12.8                 | 2 (5)                           |
| 40–49   | 9 (22.5)     | 7                     | 8.7                  | 8 (20)                          |
| 50–59   | 10 (25)      | 5.2                   | 6.6                  | 7 (17.5)                        |
| 60–69   | 13 (32.5)    | 3.4                   | 3.9                  | 5 (12.5)                        |
| ≥70   | 6 (15)       | 3.5                   | 4.1                  | 2 (5)                           |
| T-stage                                       |              |                       |                      |                                 |
| x   | 6 (15)       | 6.6                   | 8.2                  | 4 (10)                          |
| 1   | 6 (15)       | 6.4                   | 7.7                  | 4 (10)                          |
| 2   | 9 (22.5)     | 6.3                   | 7.7                  | 8 (20)                          |
| 3   | 7 (17.5)     | 3.8                   | 4.3                  | 2 (5)                           |
| 4   | 9 (22.5)     | 2.7                   | 3.6                  | 4 (10)                          |
| Not documented                                | 3 (7.5)      | 4.8                   | 6.1                  | 2 (5)                           |
| N-stage                                       |              |                       |                      |                                 |
| 0   | 13 (32.5)    | 2.3                   | 2.7                  | 3 (7.5)                         |
| 1   | 6 (15)       | 5.9                   | 7.2                  | 4 (10)                          |
| 2   | 18 (45)      | 6.8                   | 8.3                  | 16 (40)                         |
| 3   | 1 (2.5)      | 3.7                   | 4.5                  | 0 (0)                           |
| Unknown                                       | 2 (5)        | 4.8                   | 6.4                  | 1 (2.5)                         |
| Surgery                                       |              |                       |                      |                                 |
| None  | 14 (35)      | 5.2                   | 6.4                  | 9 (22.5)                        |
| Primary excision                              | 8 (20)       | 5.9                   | 6.9                  | 5 (12.5)                        |
| Neck dissection                               | 6 (15)       | 6                     | 8.2                  | 4 (10)                          |
| Both  | 12 (30)      | 3.4                   | 4.2                  | 6 (15)                          |
| Chemotherapy                                  |              |                       |                      |                                 |
| None  | 18 (45)      | 3.6                   | 4.2                  | 8 (20)                          |
| Induction                                     | 2 (5)        | 3.1                   | 4.3                  | 1 (2.5)                         |
| Concurrent                                    | 9 (22.5)     | 6                     | 7.5                  | 6 (15)                          |
| Both  | 11 (27.5)    | 6.9                   | 8.5                  | 9 (22.5)                        |
| Prophylactic PEG                              |              |                       |                      |                                 |
| No  | 15 (37.5)    | 4.3                   | 5.2                  | 8 (20)                          |
| Yes   | 25 (62.5)    | 5.5                   | 6.7                  | 16 (40)                         |

Abbreviation: PEG, percutaneous endoscopic gastrostomy.




Figure 1. Range of weight loss.

prophylactic percutaneous endoscopic gastrostomy tubes (PEG). One patient struggled to eat and lost weight post-surgery and one patient reported 3–4 months of unintended weight loss before diagnosis. A total of 28 patients had weight measurements for every week of treatment, the remainder had 1 or more weeks missing.

The range of weight loss was from 1 kg (1.8%) gained to 13.4 kg (15.9%) lost (Figure 1). The mean change was a reduction of 5.0 kg (SD = 3.7)/6% (SD = 4.4). Three (7.5%) patients gained weight throughout radiotherapy, 14 (35%) lost  $\leq 5\%$ , 17 (42.5%) lost  $>5\%$  and  $\leq 10\%$ , and six (15%) lost  $>10\%$ .

### Risk factors

Age, T-stage, nodal status, start weight and radiotherapy dose were tested for correlation with weight loss. Age and T-stage were negatively correlated, while nodal status and dose were positively correlated. Two patients were considerably younger (F: 17 and M: 28 years) than the next youngest (43 years) and the mean (57 years); and both suffered severe weight loss (9.2 and 11 kg; 14.2 and 11.4%, respectively). Correlation was recalculated without these data

and while the correlation coefficient reduced it was still significant ( $p = 0.001$ ). Start weight approached, but did not achieve significance, for absolute weight loss.

Independent paired samples were tested using the Kolmogorov–Smirnov Z test. There was a significant increase in median % weight loss for patients receiving either concurrent, or induction and concurrent chemotherapy. Receipt of any chemotherapy versus none approached significance for both absolute and percentage weight loss.

For nominal variables with several categories the Kruskal–Wallis one-way analysis of variance was used. Chemotherapy (none versus induction versus concurrent versus both) and site both approached significance for absolute weight loss. Percentage weight loss showed significant differences according to chemotherapy regime ( $p = 0.031$ ). Patients receiving combined induction and concurrent chemotherapy demonstrated significantly more weight loss than those who did not receive any ( $p = 0.033$ ). Site approached significance for percentage weight loss.

Multiple linear regression analysis was used to identify predictive factors using the variables

**Table 2.** Multiple regression for absolute and percentage weight loss

| Variables                         | Coefficient | Standardised coefficient | 95% CI           | p      | Adjusted R <sup>2</sup> |
|-----------------------------------|-------------|--------------------------|------------------|--------|-------------------------|
| <b>Absolute weight loss (kg)</b>  |             |                          |                  |        |                         |
| Age                               | -0.14       | -0.465                   | -0.228 to -0.052 | 0.003  | 0.421                   |
| N-stage                           | 1.554       | 0.402                    | 0.428 to 2.68    | 0.009  |                         |
| Constant                          | 11.092      |                          | 5.585 to 16.598  | <0.001 |                         |
| <b>Percentage weight loss (%)</b> |             |                          |                  |        |                         |
| Age                               | -0.117      | -0.39                    | -0.215 to -0.02  | 0.02   | 0.383                   |
| Node +                            | 2.927       | 0.382                    | 0.436 to 5.418   | 0.023  |                         |
| Constant                          | 9.716       |                          | 3.229 to 16.203  | 0.005  |                         |
| Age                               | -0.164      | -0.547                   | -0.251 to -0.078 | 0.001  | 0.406                   |
| Number of nodal levels            | 1.116       | 0.375                    | 0.257 to 1.974   | 0.013  |                         |
| Constant                          | 13.108      |                          | 7.993 to 18.223  | <0.001 |                         |
| <b>Absolute weight loss (kg)</b>  |             |                          |                  |        |                         |
| Age                               | -0.191      | -0.528                   | -0.288 to -0.094 | <0.001 | 0.511                   |
| N-stage                           | 1.912       | 0.412                    | 0.669 to 3.154   | 0.004  |                         |
| Constant                          | 14.67       |                          | 8.597 to 20.743  | <0.001 |                         |
| Age                               | -0.165      | -0.456                   | -0.274 to -0.055 | 0.005  | 0.463                   |
| Node +                            | 3.484       | 0.378                    | 0.694 to 6.274   | 0.016  |                         |
| Constant                          | 13.165      |                          | 5.899 to 20.431  | 0.001  |                         |
| Age                               | -0.221      | -0.611                   | -0.316 to -0.126 | <0.001 | 0.502                   |
| Number of nodal levels            | 1.403       | 0.393                    | 0.460 to 2.346   | 0.005  |                         |
| Constant                          | 17.115      |                          | 11.496 to 22.735 | <0.001 |                         |

identified as significant. To avoid co-linearity separate analyses were run for chemotherapy regimes. For both absolute and percentage weight loss, age and nodal status were the only predictive factors (Table 2). All combinations of categories were tested and each provided the same outcome regarding significant predictive factors.

## DISCUSSION

Weight loss has long been recognised as a problem<sup>23</sup>; and remains a clinically significant complication of H&N radiotherapy.

Not all patients will lose weight, but many do, with some having experienced some degree of weight loss as either symptomatic of disease, or related to previous treatment interventions.<sup>24,25</sup> In this study mean weight loss was similar, although at the top end of the range reported in other studies<sup>20,21,24</sup> (Table 3). A total of 60% (24) patients had severe weight loss (>5%), which is higher than that reported at the end of radiotherapy in other studies<sup>20,22</sup>; 15% (six) patients lost >10% body weight throughout radiotherapy, fewer than the 74.2% reported by

Munshi et al.,<sup>26</sup> but similar to Mallick et al.<sup>22</sup> and Langius et al.<sup>20</sup>

Final weight measurements were taken during the last week of radiotherapy (in some cases earlier if final week data were not available). Mallick et al.<sup>22</sup> studied up to 1 month post-radiotherapy; 52 out of 103 patients had data for this time point. Mean weight loss was higher than at the end of radiotherapy (4.1 versus 3.8%) but rates of weight loss >5% were similar (36.5 versus 37.9%). Nutritional scores in Britton et al.<sup>27</sup> were at their worst at the end of radiotherapy and improved by 4 weeks post-radiotherapy. Ehrsson et al.<sup>21</sup> and Otosson et al.<sup>28</sup> conducted longer follow-ups and found that weight loss peaked at 6 and 5 months, respectively. Langius et al.<sup>20</sup> had data at 2 years post-radiotherapy for malnourished (weight loss >5%) patients (44% of the cohort), 73% of whom had not recovered to baseline weight. It seems reasonable to expect that patients in this cohort would have continued losing weight in the weeks and months following radiotherapy.

Linear regression showed nodal status and age to be predictive of weight loss. Correlations were stronger for percentage over absolute weight loss.

Table 3. Key points

| Study                          | Mean weight loss during RT              | Risk factors   | Mean age    | Number of patients | Patients losing >5%      |
|--------------------------------|---|--|-------------|--------------------|--------------------------|
| Audit                          | 5 kg (6%)                               | Nodal involvement, younger age   | 56.6        | 40                 | 24 (60%)                 |
| Britton et al. <sup>27</sup>   |   | Baseline depression, time, tumour site   | 63.6        | 58                 |                          |
| Nourissat et al. <sup>24</sup> | 2.2 kg (3%)                             | Tumour site (non-glottic), higher stage of disease, higher weight at start of RT, dysphagia/odynophagia at baseline, reduced energy intake during RT, mucositis during RT, constipation during RT and other digestive symptoms during RT             | 62.4        | 535                |                          |
| Ehrsson et al. <sup>21</sup>   | 4.2 kg (5.4%)                           | Advanced tumour stage  | 60.4        | 157                | 73% (at 6 months)<br>38% |
| Mallik et al. <sup>22</sup>    | 2.4 kg (3.8%)                           | Oropharyngeal tumours, receipt of chemoradiotherapy, doses >60 Gy and larger PTVs (both prescribed and elective)   | 55.3        | 113                |                          |
| Langius et al. <sup>20</sup>   | 4 kg (5%)                               | Dry mouth, nodal irradiation   | 66          | 238                | 44%                      |
| Ottosson et al. <sup>28</sup>  | 9.4 kg (11.3%) (up to 5 months post RT) | Age <65, oropharyngeal primaries, high BMI at start of RT, a high performance status at the start of RT, absence of swallowing problems at the start of RT, a lack of tube feeding at the start of RT and the presence of mucositis at the end of RT | 62 (median) | 712                |                          |
| Munshi et al. <sup>26</sup>    |   | Poor performance status, chemoradiotherapy and doses >60 Gy  |             | 140                |                          |

Abbreviations: RT, radiotherapy; PTV, planning target volume; BMI, body mass index.

Percentage weight loss adjusts for differences in start weight, which can be significant, particularly between genders.

### Treatment characteristics

Chemotherapy and radiotherapy doses were associated with increased weight loss in this study, but neither was predictive. Previous studies have found chemoradiotherapy and radiotherapy doses >60 Gy were both associated with increased weight loss.<sup>22,26</sup> Concurrent chemotherapy and higher doses of radiotherapy are known to increase toxicity, potentially leading to dysphagia, reducing capacity for oral intake.<sup>29</sup> The associated risk of weight loss is therefore understandable. Interestingly, the cohort studied by Langius et al.<sup>20</sup> did not receive chemotherapy, yet still showed proportionally similar weight loss. As radiotherapy doses are unlikely to be reduced, patients receiving the higher doses may require closer surveillance and additional support in attempts to minimise weight loss.

### Patient characteristics

Munshi et al.<sup>26</sup> identified poor performance status (PS) to be associated with increased weight loss, whereas Ottosson et al.<sup>28</sup> found the opposite. Theoretically, patients with lower PS would do worse; however, if these patients are identified before treatment as at risk, early intervention may minimise weight loss. PS may reflect the preferences of the centre studied rather than any patient or treatment related characteristic; although it should be noted that Ottosson et al.<sup>28</sup> was a multicentric study.

Younger patients lost more weight in this study and age was predictive, while other studies have also observed increased weight loss for younger patients,<sup>20,28</sup> although neither were predictive and others have found no association with age.<sup>21</sup> Despite the latter, there appears to be a trend of younger patients losing more weight, possibly associated with more aggressive treatments, or psychological impact. Further study in this area is required to understand causal relationships and potential corrective interventions, whether they be nutritional, or psychological.

Start weight has been found to be weakly associated, but predictive of weight loss.<sup>24</sup> Another study used body mass index measures, which showed significant differences in weight loss between overweight/obese and normal/underweight patients.<sup>28</sup> Percentage weight loss accounts for differences in start weight at baseline. If weight loss is used as indicative of malnutrition, relative values are more reliable as the clinical relevance of a 5 kg reduction can vary according to the patient's start weight.

Other identified risk factors for increased weight loss include the presence of dysphagia at baseline<sup>24</sup> and no swallowing problems at baseline<sup>28</sup> reduced energy intake throughout radiotherapy, the presence of digestive symptoms during radiotherapy,<sup>24</sup> xerostomia<sup>20</sup> and mucositis during radiotherapy.<sup>24,28</sup> Mucositis and xerostomia are notable factors that potentially limit oral intake, perhaps explaining reduced intake.

Studies have largely focussed on clinical factors, and easily defined patient characteristics such as age, cohabitation or smoking status. Only one study was found that investigated psychological factors; showing depression as predictive of weight loss, a factor considered potentially modifiable, offering a new avenue for minimising weight loss.<sup>27</sup> The lack of study in this area also suggests that depression may be an aspect of cancer care that is not being fully addressed.

### Disease characteristics

This audit found nodal status to be predictive of weight loss, while Mallick et al.<sup>22</sup> found that larger PTVs were predictive. In the study by Langius et al.<sup>20</sup> irradiation of neck nodes was the most reliable factor for predicting significant weight loss. Node positive patients and those at risk of nodal involvement require larger PTVs to encompass the volume designated for radical or elective irradiation. Consequently, the volume of tissue included in the high dose region is greater, increasing the severity and extent of toxicities. This could help to explain the higher risk of weight loss, either through increased metabolic demands or reduced oral capacity.

Mallick et al.<sup>22</sup> also analysed N-stage, comparing N0/1 versus N2/3, which had no associated

difference. N1 patients would ordinarily receive a radical dose to involved nodes and an elective dose to the next level nodes; whereas N0 patients may have no nodal irradiation, depending on risk factors. Combining N0-1 may hide differences between node positive and node negative patients. Nodal status or PTV volume, strongly suggest that radiotherapy related toxicity is an important causal factor in weight loss and could be used to reliably indicate patients at risk.

Here, T-stage was negatively correlated with weight loss, whereas other studies have shown weight loss to increase with stage.<sup>20,21</sup> Positive correlation between stage and weight loss is more intuitive as the expected impact of more advanced disease requiring wider treatment fields would be increased toxicity for these patients. This perhaps indicates that higher stage patients at the study centre are identified as at risk and managed proactively; or that they are considered less able to tolerate intense treatment and thus suffered less severe toxicities.

Differences were observed between primary sites, although were not significant upon analysis. Some studies have shown that oropharyngeal tumours were predictive of increased weight loss<sup>22,28</sup> and others with non-glottic tumour showed increased weight loss.<sup>24</sup> However, Langius et al.<sup>20</sup> only studied early stage laryngeal patients who displayed similar rates of weight loss to studies of heterogeneous primary site. Primary site has been identified as a factor in previous studies, but if taken as a sole predictor leaves many patients at risk, impairing both the quality of treatment and support received. Discomfort from treatment related toxicity of swallowing structures can help explain this trend,<sup>30</sup> as can a weakening of musculature associated with swallowing if included in treatment fields.<sup>31</sup>

### Enteral feeding

The discrepancy noted above regarding the presence of swallowing problems seems indicative of patient management. In Ottosson et al.,<sup>28</sup> 76 (10%) patients received enteral nutrition from the start of radiotherapy, this included patients with swallowing problems. That figure increased to 335 (47%) patients by the end of radiotherapy.

By contrast only 14 (3%) patients received enteral nutrition in Nourissat et al.,<sup>24</sup> whereas 29 (6%) patients started radiotherapy with oral supplements, rising to 275 (51%) during radiotherapy.

There is no consensus on prophylactic enteral feeding as evidence shows both positive and negative outcomes. In the audit department prophylactic PEGs are offered only to patients undergoing chemoradiation.

It has been suggested that enteral feeding helps to prevent malnutrition,<sup>28</sup> as has been demonstrated in numerous studies.<sup>32–36</sup> The European Society for Clinical Nutrition and Metabolism recommend the use of enteral feeding where prolonged reduced nutritional intake is anticipated, for example, through obstruction or treatment related side effects.<sup>37</sup> However, enteral feeding has been linked with increased dysphagia, potentially explained by reduced exercise of the swallowing musculature.<sup>38–40</sup> Prophylactic feeding tubes may encourage cessation of oral intake earlier than would otherwise be the case, increasing tube dependency.<sup>41</sup>

In Ottosson et al.<sup>28</sup> patients without prophylactic enteral feeding exhibited increased weight loss, whereas the study by Ehrsson et al.<sup>21</sup> showed patients receiving enteral nutrition were associated with increased weight loss. In the latter three (2%) patients received prophylactic enteral nutrition while 89 (56%) started during or after completion of radiotherapy. Enteral nutritional intervention was predominantly reactive in both studies, and therefore, is not predictive. These studies suggest that reactive enteral nutrition alone is not effective in combatting weight loss. This study observed a trend for increased weight loss in the PEG group but this did not obtain significance.

Weight loss and malnutrition are prevalent in H&N patients before, during and after radiotherapy.<sup>20,21,28</sup> Potential predictive factors for weight loss were identified in this study. Several other studies have been carried out with similar aims, most have been retrospective and as yet no clear model has emerged. Identified risk factors include primary tumour site, high starting weight, extent of dysphagia, chemoradiotherapy,

radiotherapy dose, PS, stage of disease and depression.<sup>21,22,26–28</sup> The full aetiology of weight loss is not yet known, nor is the extent of risk factors fully understood. Studies often appear contradictory, as they can reflect how patients are managed at different centres as much as they identify genuine risk factors for weight loss. This study emphasises the requirement for nutritional support for H&N cancer patients and offers some insight into factors predicting for weight loss.

### Study limitations

A small sample limited the power of the study. Data were collected entirely from patient notes of those who had completed treatment restricting the range of variables that could be tested. Data were not available for every patient in every variable, effectively reducing the sample size for those variables.

Nonetheless, this study can help to inform future practice. Weight loss remains a problem for H&N patients. Nodal status and age were identified as predictive factors and both have been identified in other studies helping to verify their significance.<sup>20,28</sup> Factors identified by other studies, such as site, or PS were not so here<sup>26,28</sup>; substantiating claims that weight loss is complex and multifactorial.<sup>27</sup> As a guideline for clinical use age and N-stage are readily available and could be informative in assessing a patient's risk of weight loss.

### Implications for practice

Further investigation is required to better understand this phenomenon. Prospective study may help to clarify risk factors and could be augmented with self-report questionnaires and a larger sample. Ultimately more robust study will provide opportunity to develop a clinical model for predicting weight loss and malnutrition; allowing for assessment, identification and stratification of patients at risk of weight loss.

### CONCLUSION

Weight loss is common among H&N cancer patients. In recent years attempts have been made to identify causes and risk factors. In this study



weight loss was typical, with 60% patients losing >5% of their starting body weight. Age and nodal status were identified as predictive factors in this cohort. The reasons behind weight loss are likely to be complex and multifactorial. The need for further study is two-fold:

1. To better understand weight loss, enabling early identification of at risk patients and to provide the required level of nutritional support.
2. To evaluate the effectiveness of nutritional interventions to understand what nutritional support should entail.

### Acknowledgement

With thanks to Sheffield Teaching Hospitals NHS Trust for granting permission for this project to be carried out.

### Financial Support

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

### Conflicts of Interest

None.

### References

1. Argiris A, Karamouzis M V, Raben D, Ferris R L. Head and neck cancer. *Lancet* 2008; 371 (9625): 1695–1709.
2. Bhide S A, Nutting C M. Advances in radiotherapy for head and neck cancer. *Oral Oncol* 2010; 46 (6): 439–441.
3. Otto K. Volumetric modulated arc therapy: IMRT in a single gantry arc. *Med Phys* 2008; 35 (1): 310–317.
4. Slotman B J, Doornaert P, Bieker M, Senan S. RapidArc planning and delivery in patients with locally advanced head-and-neck cancer undergoing chemoradiotherapy. *Int J Radiat Oncol Biol Phys* 2011; 79 (2): 429–435.
5. Hansen E K, Xia P, Quivey J, Weinberg V, Bucci M K. The roles of repeat CT imaging and re-planning during the course of IMRT for patients with head and neck cancer. *Int J Radiat Oncol Biol Phys* 2004; 60 (1): S159.
6. Barker J, Jerry L, Garden A S et al. Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. *Int J Radiat Oncol Biol Phys* 2004; 59 (4): 960–970.
7. Winkler P, Lodron G, Mayer H et al. 1206 poster susceptibility of intensity modulated (arc) therapies on morphological changes in the head and neck region. *Radiother Oncol* 2011; 99: S449–S450.
8. Brown E, Porceddu S, Owen R, Harden F. Developing an adaptive radiotherapy technique for virally mediated head and neck cancer. *J Med Imag Radiat Sci* 2013; 44 (3): 134–140.
9. Court L E, Tishler R B, Petit J, Cormack R, Chin L. Automatic online adaptive radiation therapy techniques for targets with significant shape change: a feasibility study. *Phys Med Biol* 2006; 51 (10): 2493–2501.
10. Moinuddin S A, Kilkenny M, Davies P et al. 1207 poster towards adaptive re-planning of H/N IMRT patients: an audit of the change in ‘neck’ volume during treatment. *Radiother Oncol* 2011; 99: S450.
11. Garg S, Yoo J, Winquist E. Nutritional support for head and neck cancer patients receiving radiotherapy: a systematic review. *Support Care Cancer* 2010; 18 (6): 667–677.
12. Donovan M, Glackin M. The lived experience of patients receiving radiotherapy for head and neck cancer: a literature review. *Int J Palliat Nurs* 2012; 18 (9): 448–455.
13. NICE. 2006: Nutrition support in adults: oral nutrition support, enteral feeding tube and parenteral nutrition (CG32) [online]. <http://www.nice.org.uk/nicemedia/live/10978/29979/29979.pdf>. Accessed 6<sup>th</sup> May 2014.
14. Ravasco P, Monteiro-Grillo I, Marques Vidal P, Camilo M E. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. *Head Neck* 2005; 27 (8): 659–668.
15. van den Berg M G A, Rasmussen-Conrad E L, van Nispen L, van Binsbergen J J, Merckx M A W. A prospective study on malnutrition and quality of life in patients with head and neck cancer. *Oral Oncol* 2008; 44 (9): 830–837.
16. Head B A, Heitz L, Keeney C et al. The relationship between weight loss and health-related quality of life in persons treated for head and neck cancer. *Support Care Cancer* 2011; 19 (10): 1511–1518.
17. Nitenberg G, Raynard B. Nutritional support of the cancer patient: issues and dilemmas. *Crit Rev Oncol Hematol* 2000; 34 (3): 137–168.
18. Datema F R, Ferrier M B, Baatenburg de Jong R J. Impact of severe malnutrition on short-term mortality and overall survival in head and neck cancer. *Oral Oncol* 2011; 47 (9): 910–914.
19. ESPEN 2004 Basic in clinical nutrition, 3rd edition. Prague: House Galén.
20. Langius J A E, Doornaert P, Spreeuwenberg M D, Langendijk J A, Leemans C R, van Bokhorst-de van der Schueren, Marian A E. Radiotherapy on the neck nodes predicts severe weight loss in patients with early stage laryngeal cancer. *Radiother Oncol* 2010; 97 (1): 80–85.

21. Ehrsson Y T, Langius-Eklöf A, Laurell G et al. Nutritional surveillance and weight loss in head and neck cancer patients. *Support Care Cancer* 2012; 20 (4): 757–765.
22. Mallick I, Gupta S K, Ray R et al. Predictors of weight loss during conformal radiotherapy for head and neck cancers – How important are planning target volumes? *Clin Oncol (R Coll Radiol)* 2013; 25 (9): 557–563.
23. Johnston C A, Keane T J, Prudo S M. Weight loss in patients receiving radical radiation therapy for head and neck cancer: a prospective study. *JPEN J Parenter Enteral Nutr* 1982; 6 (5): 399–402.
24. Nourissat A, Bairati I, Fortin A et al. Factors associated with weight loss during radiotherapy in patients with stage I or II head and neck cancer. *Support Care Cancer* 2012; 20 (3): 591–599.
25. Capuano G, Gentile P C, Bianciardi F, Tosti M, Palladino A, Di Palma M. Prevalence and influence of malnutrition on quality of life and performance status in patients with locally advanced head and neck cancer before treatment. *Support Care Cancer* 2010; 18 (4): 433–437.
26. Munshi A, Pandey M B, Durga T, Pandey K C, Bahadur S, Mohanti B K. Weight loss during radiotherapy for head and neck malignancies: what factors impact it? *Nutr Cancer* 2003; 47 (2): 136–140.
27. Britton B, Clover K, Bateman L et al. Baseline depression predicts malnutrition in head and neck cancer patients undergoing radiotherapy. *Support care cancer* 2012; 20 (2): 335–342.
28. Ottosson S, Zackrisson B, Kjellén E, Nilsson P, Laurell G. Weight loss in patients with head and neck cancer during and after conventional and accelerated radiotherapy. *Acta Oncol* 2013; 52 (4): 711–718.
29. Platteaux N, Dirix P, Dejaeger E, Nuyts S. Dysphagia in head and neck cancer patients treated with chemoradiotherapy. *Dysphagia* 2010; 25 (2): 139–152.
30. Murphy B A, Gilbert J. Dysphagia in head and neck cancer patients treated with radiation: assessment, sequelae, and rehabilitation. *Semin Radiat Oncol* 2009; 19 (1): 35–42.
31. Deantonio L, Masini L, Brambilla M, Pia F, Krengli M. Dysphagia after definitive radiotherapy for head and neck cancer. *Strahlenther Onkol* 2013; 189 (3): 230–236.
32. Beaver M E, Matheny K E, Roberts D B, Myers J N. Predictors of weight loss during radiation therapy. *Otolaryngol Head Neck Surg* 2001; 125 (6): 645–648.
33. Nugent B, Parker M J, McIntyre I A. Nasogastric tube feeding and percutaneous endoscopic gastrostomy tube feeding in patients with head and neck cancer. *J Hum Nutr diet* 2010; 23 (3): 277–284.
34. Beer K T, Krause K B, Zuercher T, Stanga Z. Early percutaneous endoscopic gastrostomy insertion maintains nutritional state in patients with aerodigestive tract cancer. *Nutr Cancer* 2005; 52 (1): 29–34.
35. Wiggenraad R G J, Flierman L, Goossens A et al. Prophylactic gastrostomy placement and early tube feeding may limit loss of weight during chemoradiotherapy for advanced head and neck cancer, a preliminary study. *Clin Otolaryngol* 2007; 32 (5): 384–390.
36. Assenat E, Thezenas S, Flori N et al. Prophylactic percutaneous endoscopic gastrostomy in patients with advanced head and neck tumors treated by combined chemoradiotherapy. *J Pain Symptom Manage* 2011; 42 (4): 548–556.
37. Arends J, Bodoky G, Bozzetti F et al. ESPEN guidelines on enteral nutrition: non-surgical oncology. *Clin Nutr* 2006; 25: 245–259.
38. Langmore S, Krisciunas G P, Miloro K V, Evans S R, Cheng D M. Does PEG use cause dysphagia in head and neck cancer patients? *Dysphagia* 2012; 27 (2): 251–259.
39. Corry J, Poon W, McPhee N et al. Prospective study of percutaneous endoscopic gastrostomy tubes versus nasogastric tubes for enteral feeding in patients with head and neck cancer undergoing (chemo)radiation. *Head Neck* 2009; 31 (7): 867–876.
40. Stuart K, Luu Q, Farwell D G et al. Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer. *Int J Radiat Oncol Biol Phys* 2010; 78 (4): 1026–1032.
41. Oozeer N B, Corsar K, Glore R J, Penney S, Patterson J, Paleri V. The impact of enteral feeding route on patient-reported long term swallowing outcome after chemoradiation for head and neck cancer. *Oral Oncol* 2011; 47 (10): 980–983.